Efficacy of esaxerenone-a nonsteroidal mineralocorticoid receptor blocker-on nocturnal hypertension

Affiliations

¹ Department of Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan. morimoto.satoshi@twmu.ac.jp.
² Department of Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.

Editorial

Satoshi Morimoto et al. Hypertens Res. 2022 Feb.

. 2022 Feb;45(2):376-377.

doi: 10.1038/s41440-021-00803-1. Epub 2021 Nov 26.

¹ Department of Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan. morimoto.satoshi@twmu.ac.jp.
² Department of Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.

No abstract available

Comment on

Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes.
Kario K, Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Kario K, et al. Hypertens Res. 2022 Jan;45(1):97-105. doi: 10.1038/s41440-021-00756-5. Epub 2021 Oct 15. Hypertens Res. 2022. PMID: 34650195 Free PMC article.

1. Fagard RH. Dipping pattern of nocturnal blood pressure in patients with hypertension. Expert Rev Cardiovasc Ther. 2009;7:599–605. - DOI
1. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension. 2011;57:3–10. - DOI
1. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15:333–9. - DOI
1. Saruta T, Kageyama S, Ogihara T, Hiwada K, Ogawa M, Tawara K, et al. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens. 2004;6:175–83. - DOI
1. Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharm. 2015;761:226–34. - DOI